Page 2 - Biosolution Baltimore News Today

With production nixed at a Baltimore plant—and its shot’s role in the U.S. vaccination scheme uncertain—AstraZeneca may turn to one of its established pandemic manufacturing partners to crank out doses for the feds.

NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has ...

Lawmakers Grill Vaccine Factory Executives About Manufacturing Mistakes at 1:15 pm NPR As Emergent BioSolutions Baltimore factory was throwing away unfinished COVID-19 vaccine doses and struggling to pass muster with the Food and Drug Administration, the company awarded at least $3 million in bonuses to a handful of executives, according to documents released by a congressional subcommittee Wednesday. The House Select Subcommittee on the Coronavirus Crisis grilled executives ...

Pool / Getty Images As Emergent BioSolutions Baltimore factory was throwing away unfinished COVID-19 vaccine doses and struggling to pass muster with the Food and Drug Administration, the company awarded at least $3 million in bonuses to a handful of executives, according to documents released by a congressional subcommittee Wednesday. The House Select Subcommittee on the Coronavirus Crisis grilled executives from Emergent, which was awarded a $628 million contract with the federal governm...

  OTTAWA -- It could be weeks before Health Canada is able to say for sure whether the first delivery of 300,000 Johnson & Johnson COVID-19 vaccine doses can be used due to the ongoing quality control review, according to the agency’s chief medical adviser. “Were still getting more information. Just this past week we had additional information from Johnson & Johnson about the quality of those lots, weve got our scientists reviewing that. So we will have more information in the nex...

Home / Top News / ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – EBS ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – EBS NEW YORK, May 14, 2021 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor right...

US expands ride programs to boost vaccine acceptance Updated May 11, 2021, 4:15 p.m. Email to a Friend Jane Ellen Norman, 12, held vaccination cards for her and her 14-year-old brother Owen outside Mercedes-Benz Stadium in Atlanta on Tuesday. The two were vaccinated Tuesday morning after US regulators expanded use of Pfizers COVID-19 shot to those as young as 12.Angie Wang/Associated Press The White House announced new efforts to vaccinate Americans, including an expansion of free rides from Ub...

Home / Top News / EBS INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – EBS EBS INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – EBS NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds pu...

Share this article NEW YORK, May 4, 2021 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through March 31, 2021, inclusive (the "Class Period"), of the important June 18, 2021 lead plaintiff deadline. SO WHAT: If you purchased Emergent BioSolutions securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...

LOS ANGELES, CA / ACCESSWIRE / May 3, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE:EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.